Search
SOLACI Congress
HomeCONGRESS

CONGRESS

View Category
Chronic Ischemic cardiopathy

ESC 2019 | CLARIFY: Symptoms Predict Risk Only in Patients with Prior MI

The 5-year follow up of patients with chronic stable angina (or as the guidelines currently call it...
solaci -
Learn More
Other

ESC 2019 | EVOPACS: Evolocumab to Reduce Cholesterol in Acute Coronary Syndromes

Eight weeks of treatment with evolocumab added to a regimen of high-intensity statins in patients with acute...
solaci -
Learn More
Chronic Ischemic cardiopathy

ESC 2019 | Pure: Body Mass Index Shows Low Correlation with Cardiovascular Events

This population study has found all-cause mortality is lower the lower body mass index (BMI) is, but...
solaci -
Learn More
Other

ESC 2019 | HOPE 4: Overcoming Obstacles to Treat Risk Factors in Developing Countries

Exhaustive intervention carried out by healthcare non-medical healthcare professionals with the support of community members resulted in...
solaci -
Learn More
Chronic Ischemic cardiopathy

ESC 2019 | SYNTAXES: Ten-Year Outcomes!

The SYNTAXES (SYNTAX Extended Survival) was presented at ESC 2019 with somewhat unexpected results in favor of...
solaci -
Learn More
Antithrombotic Anticoagulants

ESC 2019 | AFIRE: Monotherapy with Rivaroxaban in Atrial Fibrillation and Stable CAD

In patients with atrial fibrillation and stable coronary artery disease who have not had revascularization procedures in...
solaci -
Learn More
Mitral valve

ESC 2019 | MITRA-FR: 2-Year Outcomes of One of the Largest Studies on MitraClip

Negative one-year outcomes of Mitra-FR led to several discussions and hypothesis, especially after the COAPT was published...
solaci -
Learn More
Other

ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups

Dapagliflozin (a sodium glucose co-transporter 2 inhibitor), when indicated concomitantly with standard therapy, reduces significantly the...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Dr. Juan Manuel Pérez - 0
Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy